BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTX · IEX Real-Time Price · USD
7.07
+0.24 (3.51%)
Feb 3, 2023, 4:00 PM EST - Market closed
3.51%
Market Cap 109.71M
Revenue (ttm) n/a
Net Income (ttm) -26.11M
Shares Out 15.52M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 135,582
Open 6.83
Previous Close 6.83
Day's Range 6.83 - 7.25
52-Week Range 4.06 - 12.09
Beta 1.38
Analysts Buy
Price Target 11.16 (+57.85%)
Earnings Date Mar 21, 2023

About BCTX

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 5
Stock Exchange NASDAQ
Ticker Symbol BCTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for BCTX stock is "Buy." The 12-month stock price forecast is $11.16, which is an increase of 57.85% from the latest price.

Price Target
$11.16
(57.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BriaCell CEO Letter to Shareholders

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

1 week ago - GlobeNewsWire

BriaCell to Investigate Alleged Illegal Trading of Public Securities

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

1 week ago - GlobeNewsWire

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia,, Jan. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

2 weeks ago - GlobeNewsWire

BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

3 weeks ago - GlobeNewsWire

BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

2 months ago - GlobeNewsWire

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technolo...

Other symbols: IPA
2 months ago - Business Wire

BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

3 months ago - GlobeNewsWire

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

3 months ago - GlobeNewsWire

BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

4 months ago - GlobeNewsWire

BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

5 months ago - GlobeNewsWire

BriaCell Announces Presentation at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

5 months ago - GlobeNewsWire

BriaCell Secures License for a Promising Novel Anti-Cancer Agent

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

6 months ago - GlobeNewsWire

BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

PHILADELPHIA and VANCOUVER, British Columbia, July 05, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

7 months ago - GlobeNewsWire

BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

7 months ago - GlobeNewsWire

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

8 months ago - GlobeNewsWire

Creatv Bio's LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days

ROCKVILLE, Md.--(BUSINESS WIRE)--Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response ...

8 months ago - Business Wire

BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...

9 months ago - GlobeNewsWire

Why Is BriaCell (BCTX) Stock Moving Today?

BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?

10 months ago - InvestorPlace

Why BriaCell Therapeutics Stock Is Surging Today

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment ...

10 months ago - Benzinga

BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

10 months ago - GlobeNewsWire

BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022

PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

10 months ago - GlobeNewsWire

BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

PHILADELPHIA and VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

10 months ago - GlobeNewsWire

BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

1 year ago - GlobeNewsWire

BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

1 year ago - GlobeNewsWire

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that all ...

1 year ago - GlobeNewsWire